AGC Biologics rolls out new viral vector platforms
Pharmaceutical Technology
MAY 17, 2023
AGC Biologics has introduced the BravoAAV and ProntoLVV viral vector platforms that offer quick clinical and commercial production and release of good manufacturing practices (GMP). Both platforms use the company’s development, manufacturing and analytical capabilities in lentiviral vector (LVV) and adeno-associated viral vector (AAV).
Let's personalize your content